A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...
Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...
Illuccix, after radiolabelling with gallium-68, is indicated in France for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in ...
LAKE MARY, Fla. & BERLIN--(BUSINESS WIRE)--RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract ...
MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 ...
Raphaël Ortiz, Chief Executive Officer, Telix International, commented, "The approval of Illuccix® in Norway will enable a clinically-validated PSMA-PET product to be more widely available, allowing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback